The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Patients and Donors
2.3. FMT Procedure and Strategy
2.4. Definition of Outcomes and Safety Assessment
2.5. Sample Collection and Non-Targeted Metabolomics Processing
2.5.1. Sample Collection
2.5.2. Sample Preparation
2.5.3. LC–MS
2.5.4. Metabolomic Data Analysis
2.6. Statistical Analysis
3. Results
3.1. Clinical Characteristics and Outcomes of the Participants
3.2. FMT Partly Improved the Perturbation of Serum Metabolome in UC Patients
3.3. The Potential of Baseline Metabolic Profiles for Prediction of Clinical Remission of FMT
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Shan, Y.; Lee, M.; Chang, E.B. The Gut Microbiome and Inflammatory Bowel Diseases. Annu. Rev. Med. 2022, 73, 455–468. [Google Scholar] [CrossRef] [PubMed]
- Costello, S.P.; Hughes, P.A.; Waters, O.; Bryant, R.V.; Vincent, A.D.; Blatchford, P.; Katsikeros, R.; Makanyanga, J.; Campaniello, M.A.; Mavrangelos, C.; et al. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. J. Am. Med. Assoc. 2019, 321, 156–164. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haifer, C.; Paramsothy, S.; Kaakoush, N.O.; Saikal, A.; Ghaly, S.; Yang, T.; Luu, L.D.W.; Borody, T.J.; Leong, R.W. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): A randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol. Hepatol. 2022, 7, 141–151. [Google Scholar] [CrossRef] [PubMed]
- Paramsothy, S.; Kamm, M.A.; Kaakoush, N.O.; Walsh, A.J.; van den Bogaerde, J.; Samuel, D.; Leong, R.W.L.; Connor, S.; Ng, W.; Paramsothy, R.; et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. Lancet 2017, 389, 1218–1228. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Ding, X.; Liu, K.; Marcella, C.; Liu, X.; Zhang, T.; Liu, Y.; Li, P.; Xiang, L.; Cui, B.; et al. Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes. Clin. Transl. Gastroenterol. 2020, 11, e00224. [Google Scholar] [CrossRef]
- Rees, N.P.; Shaheen, W.; Quince, C.; Tselepis, C.; Horniblow, R.D.; Sharma, N.; Beggs, A.D.; Iqbal, T.H.; Quraishi, M.N. Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis. EBioMedicine 2022, 81, 104088. [Google Scholar] [CrossRef]
- Kumar, M.; Garand, M.; Al Khodor, S. Integrating omics for a better understanding of Inflammatory Bowel Disease: A step towards personalized medicine. J. Transl. Med. 2019, 17, 419. [Google Scholar] [CrossRef] [Green Version]
- Gallagher, K.; Catesson, A.; Griffin, J.L.; Holmes, E.; Williams, H.R.T. Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review. J. Crohns Colitis 2021, 15, 813–826. [Google Scholar] [CrossRef]
- Weersma, R.K.; Zhernakova, A.; Fu, J. Interaction between drugs and the gut microbiome. Gut 2020, 69, 1510–1519. [Google Scholar] [CrossRef]
- Davar, D.; Dzutsev, A.K.; McCulloch, J.A.; Rodrigues, R.R.; Chauvin, J.M.; Morrison, R.M.; Deblasio, R.N.; Menna, C.; Ding, Q.; Pagliano, O.; et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 2021, 371, 595–602. [Google Scholar] [CrossRef]
- Lau, C.E.; Siskos, A.P.; Maitre, L.; Robinson, O.; Athersuch, T.J.; Want, E.J.; Urquiza, J.; Casas, M.; Vafeiadi, M.; Roumeliotaki, T.; et al. Determinants of the urinary and serum metabolome in children from six European populations. BMC Med. 2018, 16, 202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ding, X.; Li, Q.; Li, P.; Zhang, T.; Cui, B.; Ji, G.; Lu, X.; Zhang, F. Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis. Drug Saf. 2019, 42, 869–880. [Google Scholar] [CrossRef] [PubMed]
- Fecal Microbiota Transplantation-Standardization Study Group. Nanjing consensus on methodology of washed microbiota transplantation. Chin. Med. J. 2020, 133, 2330–2332. [Google Scholar] [CrossRef]
- Zhang, T.; Lu, G.; Zhao, Z.; Liu, Y.; Shen, Q.; Li, P.; Chen, Y.; Yin, H.; Wang, H.; Marcella, C.; et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: Clinical findings, animal studies and in vitro screening. Protein Cell 2020, 11, 251–266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pang, Z.; Chong, J.; Zhou, G.; de Lima Morais, D.A.; Chang, L.; Barrette, M.; Gauthier, C.; Jacques, P.E.; Li, S.; Xia, J. MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021, 49, W388–W396. [Google Scholar] [CrossRef] [PubMed]
- Speiser, J.L.; Miller, M.E.; Tooze, J.; Ip, E. A Comparison of Random Forest Variable Selection Methods for Classification Prediction Modeling. Expert Syst. Appl. 2019, 134, 93–101. [Google Scholar] [CrossRef]
- Cui, B.; Li, P.; Xu, L.; Peng, Z.; Xiang, J.; He, Z.; Zhang, T.; Ji, G.; Nie, Y.; Wu, K.; et al. Step-up fecal microbiota transplantation (FMT) strategy. Gut Microbes 2016, 7, 323–328. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lin, H.M.; Helsby, N.A.; Rowan, D.D.; Ferguson, L.R. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm. Bowel Dis. 2011, 17, 1021–1029. [Google Scholar] [CrossRef]
- Ghiboub, M.; Penny, S.; Verburgt, C.M.; Boneh, R.S.; Wine, E.; Cohen, A.; Dunn, K.A.; Pinto, D.M.; Benninga, M.A.; de Jonge, W.J.; et al. Metabolome Changes With Diet-Induced Remission in Pediatric Crohn’s Disease. Gastroenterology 2022, 163, 922–936.e15. [Google Scholar] [CrossRef]
- Zhang, F.; Wang, W.; Nie, Y.; Li, J.; He, X. From microbial technology to microbiota medicine as a clinical discipline: Sustainable development goal. Microb. Biotechnol. 2023. [Google Scholar] [CrossRef]
- Li, Y.; Luo, Z.Y.; Hu, Y.Y.; Bi, Y.W.; Yang, J.M.; Zou, W.J.; Song, Y.L.; Li, S.; Shen, T.; Li, S.J.; et al. The gut microbiota regulates autism-like behavior by mediating vitamin B6 homeostasis in EphB6-deficient mice. Microbiome 2020, 8, 120. [Google Scholar] [CrossRef] [PubMed]
- Tawk, C.; Lim, B.; Bencivenga-Barry, N.A.; Lees, H.J.; Ramos, R.J.F.; Cross, J.; Goodman, A.L. Infection leaves a genetic and functional mark on the gut population of a commensal bacterium. Cell Host Microbe 2023, 31, 811–826.e6. [Google Scholar] [CrossRef] [PubMed]
- Dugue, P.A.; Hodge, A.M.; Ulvik, A.; Ueland, P.M.; Midttun, O.; Rinaldi, S.; MacInnis, R.J.; Li, S.X.; Meyer, K.; Navionis, A.S.; et al. Association of Markers of Inflammation, the Kynurenine Pathway and B Vitamins with Age and Mortality, and a Signature of Inflammaging. J. Gerontol. A Biol. Sci. Med. Sci. 2022, 77, 826–836. [Google Scholar] [CrossRef]
- Saibeni, S.; Cattaneo, M.; Vecchi, M.; Zighetti, M.L.; Lecchi, A.; Lombardi, R.; Meucci, G.; Spina, L.; de Franchis, R. Low vitamin B6 plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: Role of inflammation and correlation with acute phase reactants. Am. J. Gastroenterol. 2003, 98, 112–117. [Google Scholar] [CrossRef] [PubMed]
- Kummen, M.; Thingholm, L.B.; Ruhlemann, M.C.; Holm, K.; Hansen, S.H.; Moitinho-Silva, L.; Liwinski, T.; Zenouzi, R.; Storm-Larsen, C.; Midttun, O.; et al. Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology 2021, 160, 1784–1798.e0. [Google Scholar] [CrossRef]
- MacMaster, M.J.; Damianopoulou, S.; Thomson, C.; Talwar, D.; Stefanowicz, F.; Catchpole, A.; Gerasimidis, K.; Gaya, D.R. A prospective analysis of micronutrient status in quiescent inflammatory bowel disease. Clin. Nutr. 2021, 40, 327–331. [Google Scholar] [CrossRef] [PubMed]
- Ueland, P.M.; McCann, A.; Midttun, O.; Ulvik, A. Inflammation, vitamin B6 and related pathways. Mol. Asp. Med. 2017, 53, 10–27. [Google Scholar] [CrossRef] [PubMed]
- Murgia, A.; Hinz, C.; Liggi, S.; Denes, J.; Hall, Z.; West, J.; Santoru, M.L.; Piras, C.; Manis, C.; Usai, P.; et al. Italian cohort of patients affected by inflammatory bowel disease is characterised by variation in glycerophospholipid, free fatty acids and amino acid levels. Metabolomics 2018, 14, 140. [Google Scholar] [CrossRef]
- Liu, X.; Beaumont, M.; Walker, F.; Chaumontet, C.; Andriamihaja, M.; Matsumoto, H.; Khodorova, N.; Lan, A.; Gaudichon, C.; Benamouzig, R.; et al. Beneficial effects of an amino acid mixture on colonic mucosal healing in rats. Inflamm. Bowel Dis. 2013, 19, 2895–2905. [Google Scholar] [CrossRef] [PubMed]
- Papada, E.; Forbes, A.; Amerikanou, C.; Torovic, L.; Kalogeropoulos, N.; Tzavara, C.; Triantafillidis, J.K.; Kaliora, A.C. Antioxidative Efficacy of a Pistacia Lentiscus Supplement and Its Effect on the Plasma Amino Acid Profile in Inflammatory Bowel Disease: A Randomised, Double-Blind, Placebo-Controlled Trial. Nutrients 2018, 10, 1779. [Google Scholar] [CrossRef] [Green Version]
- Battat, R.; Duijvestein, M.; Vande Casteele, N.; Singh, S.; Dulai, P.S.; Valasek, M.A.; Mimms, L.; McFarland, J.; Hester, K.D.; Renshaw, M.; et al. Serum Concentrations of 7alpha-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn’s Disease. Clin. Gastroenterol. Hepatol. 2019, 17, 2722–2730.e4. [Google Scholar] [CrossRef] [PubMed]
- Sinha, S.R.; Haileselassie, Y.; Nguyen, L.P.; Tropini, C.; Wang, M.; Becker, L.S.; Sim, D.; Jarr, K.; Spear, E.T.; Singh, G.; et al. Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. Cell Host Microbe 2020, 27, 659–670.e5. [Google Scholar] [CrossRef] [PubMed]
- Dai, L.; Tang, Y.; Zhou, W.; Dang, Y.; Sun, Q.; Tang, Z.; Zhu, M.; Ji, G. Gut Microbiota and Related Metabolites Were Disturbed in Ulcerative Colitis and Partly Restored After Mesalamine Treatment. Front. Pharmacol. 2020, 11, 620724. [Google Scholar] [CrossRef]
- Mullish, B.H.; McDonald, J.A.K.; Pechlivanis, A.; Allegretti, J.R.; Kao, D.; Barker, G.F.; Kapila, D.; Petrof, E.O.; Joyce, S.A.; Gahan, C.G.M.; et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 2019, 68, 1791–1800. [Google Scholar] [CrossRef] [Green Version]
- Nieman, D.C.; Meaney, M.P.; John, C.S.; Knagge, K.J.; Chen, H. 9- and 13-Hydroxy-octadecadienoic acids (9+13 HODE) are inversely related to granulocyte colony stimulating factor and IL-6 in runners after 2h running. Brain Behav. Immun. 2016, 56, 246–252. [Google Scholar] [CrossRef]
- Pellesi, L.; Verga, M.C.; De Maria, N.; Villa, E.; Pini, L.A.; Guerzoni, S. Nabilone administration in refractory chronic diarrhea: A case series. BMC Gastroenterol. 2019, 19, 105. [Google Scholar] [CrossRef] [Green Version]
- Kurata, K.; Kawahara, H.; Nishimura, K.; Jisaka, M.; Yokota, K.; Shimizu, H. Skatole regulates intestinal epithelial cellular functions through activating aryl hydrocarbon receptors and p38. Biochem. Biophys. Res. Commun. 2019, 510, 649–655. [Google Scholar] [CrossRef] [PubMed]
- Wong, X.; Carrasco-Pozo, C.; Escobar, E.; Navarrete, P.; Blachier, F.; Andriamihaja, M.; Lan, A.; Tome, D.; Cires, M.J.; Pastene, E.; et al. Deleterious Effect of p-Cresol on Human Colonic Epithelial Cells Prevented by Proanthocyanidin-Containing Polyphenol Extracts from Fruits and Proanthocyanidin Bacterial Metabolites. J. Agric. Food Chem. 2016, 64, 3574–3583. [Google Scholar] [CrossRef] [PubMed]
- Guan, S.; Jia, B.; Chao, K.; Zhu, X.; Tang, J.; Li, M.; Wu, L.; Xing, L.; Liu, K.; Zhang, L.; et al. UPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease Diagnosis. J. Proteome Res. 2020, 19, 600–609. [Google Scholar] [CrossRef] [PubMed]
- Paramsothy, S.; Nielsen, S.; Kamm, M.A.; Deshpande, N.P.; Faith, J.J.; Clemente, J.C.; Paramsothy, R.; Walsh, A.J.; van den Bogaerde, J.; Samuel, D.; et al. Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis. Gastroenterology 2019, 156, 1440–1454.e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Q.; Chen, G.; Zhu, D.; Zhang, W.; Qi, S.; Xue, X.; Wang, K.; Wu, L. Effects of dietary phosphatidylcholine and sphingomyelin on DSS-induced colitis by regulating metabolism and gut microbiota in mice. J. Nutr. Biochem. 2022, 105, 109004. [Google Scholar] [CrossRef]
- Karner, M.; Kocjan, A.; Stein, J.; Schreiber, S.; von Boyen, G.; Uebel, P.; Schmidt, C.; Kupcinskas, L.; Dina, I.; Zuelch, F.; et al. First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: A randomized, placebo-controlled trial in mesalazine-refractory courses. Am. J. Gastroenterol. 2014, 109, 1041–1051. [Google Scholar] [CrossRef] [Green Version]
- Zhang, Y.; Lu, T.; Han, L.; Zhao, L.; Niu, Y.; Chen, H. L-Glutamine Supplementation Alleviates Constipation during Late Gestation of Mini Sows by Modifying the Microbiota Composition in Feces. Biomed. Res. Int. 2017, 2017, 486286. [Google Scholar] [CrossRef] [Green Version]
- Wu, T.Y.; Zhang, H.B. Glutamine has a protective role on intestinal tissues via targeting NF-kappaB pathway in rats with sepsis. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 184–191. [Google Scholar] [CrossRef] [PubMed]
- Kretzmann, N.A.; Fillmann, H.; Mauriz, J.L.; Marroni, C.A.; Marroni, N.; Gonzalez-Gallego, J.; Tunon, M.J. Effects of glutamine on proinflammatory gene expression and activation of nuclear factor kappa B and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm. Bowel Dis. 2008, 14, 1504–1513. [Google Scholar] [CrossRef]
- Ren, W.; Yin, J.; Wu, M.; Liu, G.; Yang, G.; Xion, Y.; Su, D.; Wu, L.; Li, T.; Chen, S.; et al. Serum amino acids profile and the beneficial effects of L-arginine or L-glutamine supplementation in dextran sulfate sodium colitis. PLoS ONE 2014, 9, e88335. [Google Scholar] [CrossRef]
- Xiao, L.; Cao, W.; Liu, G.; Fang, T.; Wu, X.; Jia, G.; Chen, X.; Zhao, H.; Wang, J.; Wu, C.; et al. Arginine, N-carbamylglutamate, and glutamine exert protective effects against oxidative stress in rat intestine. Anim. Nutr. 2016, 2, 242–248. [Google Scholar] [CrossRef] [PubMed]
- Yan, S.; Hui, Y.; Li, J.; Xu, X.; Li, Q.; Wei, H. Glutamine relieves oxidative stress through PI3K/Akt signaling pathway in DSS-induced ulcerative colitis mice. Iran J. Basic Med. Sci. 2020, 23, 1124–1129. [Google Scholar] [CrossRef] [PubMed]
- Xie, D.; Li, F.; Pang, D.; Zhao, S.; Zhang, M.; Ren, Z.; Geng, C.; Wang, C.; Wei, N.; Jiang, P. Systematic Metabolic Profiling of Mice with Dextran Sulfate Sodium-Induced Colitis. J. Inflamm. Res. 2021, 14, 2941–2953. [Google Scholar] [CrossRef]
- Faure, M.; Mettraux, C.; Moennoz, D.; Godin, J.P.; Vuichoud, J.; Rochat, F.; Breuille, D.; Obled, C.; Corthesy-Theulaz, I. Specific amino acids increase mucin synthesis and microbiota in dextran sulfate sodium-treated rats. J. Nutr. 2006, 136, 1558–1564. [Google Scholar] [CrossRef] [Green Version]
- Probert, F.; Walsh, A.; Jagielowicz, M.; Yeo, T.; Claridge, T.D.W.; Simmons, A.; Travis, S.; Anthony, D.C. Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. J. Crohns Colitis 2018, 12, 1326–1337. [Google Scholar] [CrossRef] [PubMed]
- Hisamatsu, T.; Ono, N.; Imaizumi, A.; Mori, M.; Suzuki, H.; Uo, M.; Hashimoto, M.; Naganuma, M.; Matsuoka, K.; Mizuno, S.; et al. Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission. PLoS ONE 2015, 10, e0140716. [Google Scholar] [CrossRef]
- Andou, A.; Hisamatsu, T.; Okamoto, S.; Chinen, H.; Kamada, N.; Kobayashi, T.; Hashimoto, M.; Okutsu, T.; Shimbo, K.; Takeda, T.; et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009, 136, 564–574.e2. [Google Scholar] [CrossRef]
- Chen, Y.; Li, D.; Dai, Z.; Piao, X.; Wu, Z.; Wang, B.; Zhu, Y.; Zeng, Z. L-methionine supplementation maintains the integrity and barrier function of the small-intestinal mucosa in post-weaning piglets. Amino Acids 2014, 46, 1131–1142. [Google Scholar] [CrossRef] [PubMed]
- Park, I.; Pasquetti, T.; Malheiros, R.D.; Ferket, P.R.; Kim, S.W. Effects of supplemental L-methionine on growth performance and redox status of turkey poults compared with the use of DL-methionine. Poult. Sci. 2018, 97, 102–109. [Google Scholar] [CrossRef] [PubMed]
- Tang, Y.; Tan, B.; Xiong, X.; Li, F.; Ren, W.; Kong, X.; Qiu, W.; Hardwidge, P.R.; Yin, Y. Methionine deficiency reduces autophagy and accelerates death in intestinal epithelial cells infected with enterotoxigenic Escherichia coli. Amino Acids 2015, 47, 2199–2204. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Results |
---|---|
Total number, N | 44 |
Age, years, median (IQR) | 34.5 (31.0–46.8) |
Male, n (%) | 25 (56.8) |
Age at onset, years, median (IQR) | 29.0 (24.0–37.8) |
Duration of disease, years, median (IQR) | 6.8 (4.0–10.8) |
The Montreal classification, n (%) | |
E1, proctitis | 0 (0.0) |
E2, left-sided colitis | 8 (18.2) |
E3, pancolitis | 36 (81.8) |
Endoscopic score before FMT, median (IQR) | 3.0 (2.0–3.0) |
Mayo score before FMT, median (IQR) | 10.5 (8.0–12.0) |
Disease severity, n (%) | |
Mild | 2 (4.5) |
Moderate | 20 (45.5) |
Severe | 22 (50.0) |
Smoking history 1, n (%) | 8 (18.2) |
History of anal fistula surgery, n (%) | 7 (15.9) |
Treatment history before FMT, n (%) | |
5-aminosalicylate | 39 (88.6) |
Corticosteroid | 38 (86.4) |
Immunosuppressant | 10 (22.7) |
Anti-TNF antibody | 4 (9.1) |
Step-up FMT strategy | |
Step 1 | 36 (81.8) |
Step 2 | 3 (6.8) |
Step 3 | 5 (11.4) |
Clinical efficacy at three months after FMT | 22 (50.0) |
Clinical response, n (%) | 13 (29.5) |
Clinical remission, n (%) | 12 (27.3) |
Adverse events, n (%) |
Metabolite Set | Metabolite | HMDB | Rem vs. Non-Rem | |
---|---|---|---|---|
FC | p Value | |||
Glycerophosphocholines | PC (14:0/20:4(5Z,8Z,11Z,14Z)) | HMDB0007883 | 2.04 | 0.011 |
PC (14:0/20:5(5Z,8Z,11Z,14Z,17Z)) | HMDB0007885 | 3.64 | 0.018 | |
PC (16:0/18:1(9Z)) | HMDB0007972 | 1.39 | 0.005 | |
PC (16:0/22:5(7Z,10Z,13Z,16Z,19Z)) | HMDB0007990 | 1.41 | 0.018 | |
PC (16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | HMDB0007991 | 1.48 | 0.003 | |
PC (16:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | HMDB0008023 | 1.61 | 0.0002 | |
PC (18:0/20:4(5Z,8Z,11Z,14Z)) | HMDB0008048 | 1.45 | 0.0004 | |
PC (18:1(9Z)/18:2(9Z,12Z)) | HMDB0008105 | 1.65 | 0.0003 | |
PC (18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | HMDB0008123 | 1.44 | 0.038 | |
PC (18:2(9Z,12Z)/18:2(9Z,12Z)) | HMDB0008138 | 9.4 | 0.00007 | |
PC (18:3(9Z,12Z,15Z)/18:2(9Z,12Z)) | HMDB0008204 | 1.85 | 0.0002 | |
PC (18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)) | HMDB0008206 | 2.1 | 0.009 | |
PC (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:0) | HMDB0008727 | 1.5 | 0.006 | |
PC (P-16:0/16:0) | HMDB0011206 | 1.46 | 0.028 | |
PC (P-16:0/18:2(9Z,12Z)) | HMDB0011211 | 1.59 | 0.005 | |
PC (P-16:0/20:4(8Z,11Z,14Z,17Z)) | HMDB0011221 | 1.6 | 0.0001 | |
PC (P-18:0/20:4(5Z,8Z,11Z,14Z)) | HMDB0011253 | 1.35 | 0.004 | |
PC (P-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | HMDB0011262 | 1.37 | 0.031 | |
PC (o-18:2(9Z,12Z)/18:2(9Z,12Z)) | HMDB0013435 | 1.53 | 0.0002 | |
Glycerophospholipids | PC (20:4(8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)) | HMDB0008478 | 1.33 | 0.010 |
PC (20:4(8Z,11Z,14Z,17Z)/22:5(7Z,10Z,13Z,16Z,19Z)) | HMDB0008484 | 1.32 | 0.029 | |
PC (22:6(4Z,7Z,10Z,13Z,16Z,19Z)/P-16:0) | HMDB0008751 | 1.57 | 0.001 | |
PE (18:0/22:5(4Z,7Z,10Z,13Z,16Z)) | HMDB0009010 | 1.91 | 0.009 | |
PE (20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)) | HMDB0009437 | 1.65 | 0.018 | |
PC (P-18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | HMDB0011295 | 1.21 | 0.025 | |
PI (16:0/16:1(9Z)) | HMDB0009779 | 0.83 | 0.018 | |
Glycerophosphoethanolamines | PE (18:0/18:1(9Z)) | HMDB0008993 | 1.76 | 0.033 |
PE (18:0/20:4(5Z,8Z,11Z,14Z)) | HMDB0009003 | 2.04 | 0.00007 | |
PE (18:0/22:4(7Z,10Z,13Z,16Z)) | HMDB0009009 | 1.91 | 0.002 | |
PE (18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | HMDB0009012 | 1.78 | 0.014 | |
PE (18:1(9Z)/18:1(9Z)) | HMDB0009059 | 1.43 | 0.020 | |
Amino acids and peptides | L-Asparagine | HMDB0000168 | 0.88 | 0.015 |
Allantoic acid | HMDB0001209 | 0.75 | 0.024 | |
Lisinopril | HMDB0001938 | 0.73 | 0.021 | |
D-Ornithine | HMDB0003374 | 0.75 | 0.008 | |
N2-gamma-Glutamylglutamine | HMDB0011738 | 0.72 | 0.043 | |
N-Acetyl valine | HMDB0011757 | 0.63 | 0.018 | |
N-Decanoyl glycine | HMDB0013267 | 0.64 | 0.008 | |
Perindopril | HMDB0014928 | 0.27 | 0.0007 | |
Glutamyl tryptophan | HMDB0028830 | 0.51 | 0.002 | |
Tryptophyl-Lysine | HMDB0029088 | 0.7 | 0.011 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wu, X.; Li, P.; Wang, W.; Xu, J.; Ai, R.; Wen, Q.; Cui, B.; Zhang, F. The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation. Nutrients 2023, 15, 3340. https://doi.org/10.3390/nu15153340
Wu X, Li P, Wang W, Xu J, Ai R, Wen Q, Cui B, Zhang F. The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation. Nutrients. 2023; 15(15):3340. https://doi.org/10.3390/nu15153340
Chicago/Turabian StyleWu, Xia, Pan Li, Weihong Wang, Jie Xu, Rujun Ai, Quan Wen, Bota Cui, and Faming Zhang. 2023. "The Underlying Changes in Serum Metabolic Profiles and Efficacy Prediction in Patients with Extensive Ulcerative Colitis Undergoing Fecal Microbiota Transplantation" Nutrients 15, no. 15: 3340. https://doi.org/10.3390/nu15153340